Pharmacokinetic properties of Gammagard Liquid 10% (KIOVIG) administered intravenously and subcutaneously to patients with primary immunodeficiency diseases (PID)

被引：0

作者：

Schiff, R., I ^{[1
]}

Leibl, H. ^{[1
]}

Engl, W. ^{[1
]}

机构：

[1] Baxter Healthcare Corp, Westlake Village, CA USA

来源：

CLINICAL AND EXPERIMENTAL IMMUNOLOGY | 2008年 / 154卷

关键词：

D O I：

暂无

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

引用

页码：132 / 132

页数：1

共 50 条

[41] Final results of a phase I and pharmacokinetic study of γ-methylene-10-deazaaminopterin (MDAM) administered intravenously daily for five consecutive days in patients with solid tumors
Johansen, M
Zukowski, T
Hoff, PM
Newman, RA
Ni, D
Hutto, T
Abbruzzeese, J
Berghorn, E
Hausheer, F
Madden, T
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2004, 53 (05) : 370 - 376
[42] Patient and Clinical Characteristics of a Large US Sample of Patients With Primary Immunodeficiency Diseases (PID) Initiating Subcutaneous Immunoglobulin (SCIG) Therapy
Ritchey, Mary E.
Anderson-Smits, Colin
Orange, Jordan
Park, Michelle
Huang, Zhongwen
Layton, J. Bradley
JOURNAL OF CLINICAL IMMUNOLOGY, 2020, 40 (SUPPL 1) : S157 - S159
[43] Treatment preference on the new Subcutaneous Immunoglobulin 20% (SCIG 20%) treatment in patients with Primary Immunodeficiency Diseases (PID) in Europe (EU)
Gladiator, A.
Meckley, L.
Berner, T.
Engl, W.
Ito, D.
Yel, L.
SWISS MEDICAL WEEKLY, 2017, 147 : 57S - 57S
[44] Evaluating Safety, Tolerability, and Efficacy of Subcutaneous Human Immunoglobulin 16.5% Administered at Modified Dosing Regimens in Patients with Primary Immunodeficiency Diseases - Study Design
Melamed, Isaac
Gupta, Sudhir
Kobayashi, Roger
Eppolito, Michael
Maltese, Joanna
Rizvi, Syed
Kobayashi, Ai
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2021, 147 (02) : AB75 - AB75
[45] Pharmacokinetics and Safety of Subcutaneous Immune Globulin (Human), 10% Caprylate/Chromatography Purified (IGIV-C) in Patients with Primary Immunodeficiency Disease (PID)
Levy, R.
Chen, J.
Roberts, R.
Sorrells, S.
Stark, D.
Tracy, J.
Wasserman, R. L.
Gupta, S.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2010, 125 (02) : AB140 - AB140
[46] A new intravenous immune globulin, 10% liquid, triple virus reduced (IGIV, 10% TVR) - Pharmacokinetics, efficacy and safety in patients with primary immunodeficiency
Leibl, Heinz
Church, Joseph A.
Stein, Mark R.
Melamed, Isaac R.
Rubinstein, Ayre
Schneider, Lynda C.
Wasserman, Richard L.
Pavlova, Borislava G.
Birthistle, Karl
Mancini, Marianne
Fritsch, Sandor
Moore-Perry, Kerry
Ehrlich, Hartmut J.
PHARMACY WORLD & SCIENCE, 2007, 29 (05): : 500 - 500
[47] POST-AUTHORIZATION SAFETY STUDY OF HYALURONIDASE-FACILITATED SUBCUTANEOUS IMMUNOGLOBULIN 10% TREATMENT IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY DISEASES
Rubinstein, A.
Bridges, T.
McNeil, D.
Tachdjian, R.
Wedner, H.
Wasserman, R.
Leibl, H.
Rabbat, C.
Honigberg, R.
Yel, L.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2017, 119 (05) : S71 - S71
[48] Population pharmacokinetic modeling and simulation of immunoglobulin exposure with varying dosing intervals of subcutaneous immunoglobulin 20% (Ig20Gly) in patients with primary immunodeficiency diseases
Dumas, Todd
Berry, N. Seth
Wolfsegger, Martin
Jolles, Stephen
McCoy, Barbara
Yel, Leman
INTERNATIONAL IMMUNOPHARMACOLOGY, 2019, 71 : 404 - 410
[49] Interim Analysis of the Global Post Authorization Safety Study of Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 10% Treatment in Patients With Primary Immunodeficiency Diseases
Rubinstein, Arye
Bridges, Tracy
McNeil, Donald
Tachdjian, Raffi
Wedner, H. James
Wasserman, Richard L.
Leibl, Heinz
Rabbat, Christopher
Yel, Leman
JOURNAL OF CLINICAL IMMUNOLOGY, 2018, 38 (03) : 378 - 378
[50] A Multicenter, Prospective, Open Label, Historically Controlled Clinical Trial to Evaluate Efficacy and Safety in Primary Immunodeficiency Diseases (PID) Patients of Flebogamma® 5% DIF, the Next Generation of Flebogamma®
Melvin Berger
Journal of Clinical Immunology, 2007, 27 : 628 - 633

← 1 2 3 4 5 →